Products & Services · Indefinite-lived intangible assets, period increase (decrease)

Padcev — Indefinite-lived intangible assets, period increase (decrease)

Pfizer Padcev — Indefinite-lived intangible assets, period increase (decrease) remained flat by 0.0% to -$150.00M in Q4 2025 compared to the prior quarter.

Analysis

StatementSegment
First reportedQ1 2023
Last reportedQ4 2025Feb 26, 2026
Rolls up toIndefinite Lived Intangible Assets Period Increase Decrease
Metric ID: pfe_segment_padcev_indefinite_lived_intangible_assets_period_increase_decrease

Historical Data

2 years
 FY'23FY'25
Value-$2.10B-$600.00M
YoY Change—+71.4%
Range-$2.10B – -$600.00M
Avg YoY Growth+71.4%
Median YoY Growth+71.4%

Frequently Asked Questions

What is Pfizer's padcev — indefinite-lived intangible assets, period increase (decrease)?
Pfizer (PFE) reported padcev — indefinite-lived intangible assets, period increase (decrease) of -$150.00M in Q4 2025.